Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA avobenzone 2% minimum in combo sunscreens "arbitrarily imposed" -- Sun Pharma.

This article was originally published in The Tan Sheet

Executive Summary

FDA AVOBENZONE 2% MINIMUM IN COMBO SUNSCREENS "ARBITRARILY IMPOSED," SUN Pharma of Paramus, N.J. argues in Oct. 16 comments on FDA's proposed amendment to the sunscreen tentative final monograph. Published in the Sept. 16 Federal Register, the amendment designates avobenzone a Category I ingredient and allows its use as a "broad spectrum" sunscreen agent alone in concentrations up to 3% and in combination with other Category I ingredients in levels between 2%-3% ("The Tan Sheet" Sept. 23, p. 15). FDA set the 2% minimum level for avobenzone in combination sunscreens to ensure that each ingredient in a combination product contributes to the overall effectiveness.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS086260

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel